Stories

Updates: Lilly's Global COVID-19 Response

View Story

Lilly's COVID-19 Science Leads to a Second FDA Emergency Use Authorization

View Story

Time to Tear Down the Rebate Wall

View Story

When the World Called for Help with COVID-19, We Were Ready

View Story

Dave Ricks Shares About Lilly's FDA Emergency Use Authorization for a Neutralizing Antibody

View Story

An Update on Lilly’s Commitment to Quality Manufacturing

View Story

CEO Dave Ricks Shares Lilly's Principles of COVID-19 Antibody Therapy Pricing and Access

View Story

Lilly Statement Regarding NIH’s ACTIV-3 Clinical Trial

View Story

Increasing Diversity in Clinical Trials

View Story

Overcoming Barriers to Biomarker Testing in Cancer

View Story